Biodol Therapeutics, a biotech firm based in Montarnaud, France, has secured €7 million in funding from BPI France through the i-DEMO call for projects. This funding will support the company’s first-in-human clinical trials.
With backing from venture capital fund V-Bio Ventures, Biodol Therapeutics will lead a consortium that includes the Institute for Neurosciences of Montpellier and the Laboratory for Therapeutic Innovation in Strasbourg. Founded in 2015, Biodol Therapeutics is dedicated to developing innovative treatments for chronic pain, specifically targeting the Receptor Tyrosine Kinase (RTK) FLT3, which plays a crucial role in maintaining chronic neuropathic pain.
Advertisement
Innovative Pain Treatment Approaches
Biodol Therapeutics focuses on creating allosteric inhibitors of the FLT3 receptor, co-owning a portfolio of patents with prestigious French research institutions such as the Universities of Montpellier and Strasbourg, INSERM, and CNRS. The company’s program, supported by organizations including BPI France, Satt AxLR, Inserm Transfert, Region Occitanie, the French National Research Agency, SEMIA Incubator, and Montpellier Business and Innovation Centre, aligns with the France 2030 plan to boost innovative companies.
Goals and Utilization of Funds
The primary goal is to bring the clinical candidate BDT272 to trials by the end of 2024. The funds will be used to support the first human trials of BDT272, a novel pain treatment with exceptional safety and efficacy in preclinical models. Additionally, the funds will advance the development of small-molecule extracellular negative allosteric modulators (NAMs) of the FLT3 receptor.
Promising Drug Development
The FLT3 receptor is crucial in pain mechanisms, and blocking it has shown potential benefits, as highlighted in several international publications. FLT3 negative allosteric modulation is emerging as a promising approach in drug development for conditions with high medical needs.
About V-Bio Ventures
Founded in 2015, V-Bio Ventures is a venture capital firm that invests in life sciences companies, focusing on technologies that can significantly impact sectors such as biopharmaceuticals, pharmaceuticals, diagnostics, and agriculture. They work closely with VIB, a leading science institute in Belgium.
With this substantial investment, Biodol Therapeutics is poised to make significant advancements in chronic pain treatment, leveraging innovative approaches and strong support from the biotech community.
